Welcome to IGP
The department conducts advanced research and education in areas such as clinical immunology, medical genetics and genomics, pathology, oncology, vascular biology, molecular tools and medical radiation sciences.
Some of our activities are integrated with clinics at Uppsala University Hospital:
Clinical genetics
Clinical pathology
Clinical immunology and transfusion medicine
Oncology
Hospital physics
New research findings from IGP |
|
Women’s deep belly fat more strongly linked to diabetes and cardiovascular diseases A comprehensive study from IGP, with over 325,000 participants, shows that deep belly fat is a major contributing risk factor for developing diabetes and cardiovascular disease. The study also shows that deep belly fat is a larger risk factor in women compared to men. Moreover, the scientists investigated how our genes affect the accumulation of fat and present a new, simpler method to estimate the amount of deep belly fat. |
|
Three new parts of the database The Human Protein Atlas The HPA project has recently released a new version of The Human Protein Atlas. This is the most extensive update so far, with the completely new parts Blood Atlas, Brain Atlas, and a Metabolic Atlas, developed in collaboration with Chalmers University. |
|
New WHO reagent for autoantibodies in SLE patients A new study published in the journal Annals of the Rheumatic Diseases presents a WHO reference reagent produced by an international team of researchers and clinical laboratories. This reagent will facilitate the adjustment of autoantibody analyses in SLE and thereby also diagnosis and therapy for SLE patients. |
Recent publications from IGP
- Single Nuclei Transcriptome Analysis of Human Liver with Integration of Proteomics and Capture Hi-C Bulk Tissue Data
- Intratumoral expression of FoxP3-positive regulatory T-cells in T-cell lymphoma : no correlation with survival
- Predicting mortality and adverse events in patients with advanced pancreatic cancer treated with palliative gemcitabine-based chemotherapy in a multicentre phase III randomized clinical trial : the APC-SAKK risk scores
